Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Chunlei Ge†, Ruilei Li†, Haifeng Song†, Tao Geng†, Jinyan Yang†, Qinghua Tan†, Linfeng Song†, Ying Wang†, Yuanbo Xue†, Zhen Li†, Suwei Dong†, Zhiwei Zhang†, Na Zhang†, Jiying Guo†, Lin Hua†, Siyi Chen‡,³,⁴* and Xin Song†*

Abstract

Background: The primary aim of this study was to evaluate the safety of a novel dendritic cell (DC) vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 (SOCS1), and immune stimulated with flagellin for patients with stage I to IIIA non-small cell lung cancer (NSCLC) in a phase I open-label, uncontrolled, and dose-escalation trial. Moreover, we evaluate the potential efficacy of this modified DC vaccine as secondary aim.

Methods: The patients were treated with the vaccine at 1 × 10⁶, 1 × 10⁷ and the maximum dose 8 × 10⁷ at day 7, 14, and 21 after characterization of the vaccine phenotype by flow cytometry. The safety of the vaccine was assessed by adverse events, and the efficacy by the levels of several specific tumor markers and the patient quality of life.

Results: The vaccine was well tolerated without dose-limiting toxicity even at higher doses. The most common adverse event reported was just grade 1 flu-like symptoms without unanticipated or serious adverse event. A significant decrease in CD3 + CD4 + CD25 + Foxp3+ T regulatory (Treg) cell number and increase in TNF-α and IL-6 were observed in two patients. Two patients showed 15% and 64% decrease in carcino-embryonic antigen and CYFRA21, respectively. The vaccination with the maximum dose significantly improved the patients' quality of life when administered at the highest dose. More importantly, in the long-term follow-up until February 17, 2017, 1 patient had no recurrence, 1 patients had a progressive disease (PD), and 1 patient was died in the low dose group. In the middle dose group, all 3 patients had no recurrence. In the high dose group, 1 patient was died, 1 patient had a PD, and the other 7 patients had no recurrence.

Conclusions: We provide preliminary data on the safety and efficacy profile of a novel vaccine against non-small cell lung cancer, which was reasonably well tolerated, induced modest antitumor activity without dose-limiting toxicity, and improved patients' quality of life. Further more, the vaccine maybe a very efficacious treatment for patients with resected NSCLC to prevent recurrence. Our findings on the safety and efficacy of the vaccine in this phase I trial warrant future phase II/III clinical trial.

Keywords: Modified-DC vaccine, Non-small cell lung cancer (NSCLC), Phase I clinical trial
Background
Lung cancer is the leading cause of cancer mortality in both men and women, accounting for 1.2 million deaths and 1.6 million total cases in 2008 [1]. The incidence of new cases and deaths from lung cancer are increasing worldwide [2]. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases with a 16% 5-year survival rate for all stages [3]. Surgery following platinum-based chemotherapy and radiation are still the primary treatment for resectable stage I to IIIA NSCLC, with the five-year survival being 19%–50% [4]. Second-line therapy, such as Pemetrexed and Docetaxel result in slightly better survival rates, and targeted agents such as gefitinib, erlotinib, crizotinib, and bevacizumab result in prolonged overall survival or progression-free survival. However, only a small group of patients are sensitive to these targeted agents [5–10], calling for the development of new strategies against NSCLC.

Immunotherapy is an inspiring systemic strategy for provoking the immune system to attack patient tumor cells [11]. Dendritic cells (DCs) as “gatekeepers of the immune system” are the most potent antigen-presenting cells, and numerous clinical trials have shown that DC-based cancer vaccines can induce successful therapeutic and protective immune response. Notably, Provenge, a prostate cancer vaccine, exhibited promising outcomes using autologous DC pulsed with fusion antigen protein consisting of prostatic acid phosphatase (PAP) and GM-CSF, the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration in 2010, showed to prolong median OS by 4.1 months for metastatic castration resistant prostate cancer [12]. Since then, several DC vaccine clinical trials in patients with malignant glioma [13], metastatic melanoma [14] advanced hepatocellular carcinoma [15] and esophageal cancer [16, 17] have been reported. Although some of these trials did not reach the end point of primary study, others have reported positive results. Among factors that influence DC antigen presentation, such as the number, maturity state, and peptides used to pulse DC, a right peptide is the most important for a successful DC vaccine.

A large number of studies have shown that the tumor antigens survivin and MUC1 are highly expressed in variety of tumors, especially lung cancer. Survivin as a member of the inhibitor of apoptosis protein (IAP) family plays a pivotal role in inhibiting apoptosis and regulating cell division. The over-expression of surviving is correlated with unfavorable clinical outcome in many tumor types, including NSCLC [18–23]. Survivin is expressed in at least 80% of tumor patients with NSCLC, and the suppression of surviving expression abrogates survivin-mediated apoptosis, which results in increased in tumor-cell death and eventually sensitivity to anticancer therapy [24]. MUC1, a heavily glycosylated large glycoprotein, is frequently over-expressed on the cell surface of glandular epithelial cells in a variety of tumor types, including NSCLC [25, 26]. MUC1 is involved in tumorigenesis and invasiveness by modulating cell adhesion [27]. For examples, several studies have demonstrated that MUC1 expression is associated with a poor prognosis in NSCLC [28], and a number of clinical trials using MUC1 pulsed DC demonstrated positive immune response in patients with pancreatic and biliary tumors [29, 30]. However, single-antigen-loaded DCs are not sufficient to elicit stronger enough cytotoxic T-lymphocyte (CTL) response due to heterogeneity of cancer cells, whereas MUC4 and survivin-loaded DCs have been shown to successfully induce stronger CTL responses against pancreatic cancer in vitro [31]. Therefore, the combination of survivin and MUC1 may offer a new strategy for development of a DC cancer vaccine.

Interestingly, down-regulation of suppressor of cytokine signaling 1 (SOCS1), which is an attenuator of cytokine signals, promotes memory T cell responses in dendritic cells [32]. A SOCS1 suppressor antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses [33, 34]. Therefore, SOCS1 plays an essential role in negative regulation of DC antigen presentation and inhibition of DC differentiation and induces immune tolerance [35]. In fact, inhibition of SOCS1 breaks self-immune tolerance and induces effective antitumor responses [36, 37] and anti-HIV effects [38]. Furthermore, SOCS1 inhibits Toll-like receptor (TLR) signaling [39]. While the SOCS1 function in carcinogenesis among different cancer cells is still controversial, it has been suggested that modulation of SOCS1 expression in tumor cells for antitumor therapy is highly context-dependent [40]. Further studies are warranted to understand the role of SOCS1 in suppressing NSCLC.

Inhibition of SOCS1 alone is insufficient to fully activate DCs [41]. TLR signaling is important for triggering and modulating adaptive immune response through activation of DCs [42, 43]. Flagellin, a specific ligand for TLR5, plays an important role in activating immune response via triggering TLR signaling [44, 45]. A bacterial filament protein, flagellin in combination with siRNA-SOCS1 modified-DC vaccine was found to be more potent and persistent than a commercial TLR agonist in both murine and human DCs and displays a superior ability to activate HCV antigen-specific cellular and humoral immune responses [46, 47]. However, there is no DC vaccine pulsed with survivin and MUC1, silenced with SOCS1, and immune stimulated with flagellin, especially in the context of vaccine against NSCLC vaccine. Here, we evaluated the safety and efficacy of a novel modified-DC vaccine in patients with stage I to IIIA NSCLC.
Methods
Eligibility criteria
Patients with histologically confirmed stage I to IIIA NSCLC were eligible for the phase I clinical trial. The inclusion criteria included: age between 18 and 65 years; an Eastern Cooperative Oncology Group performance status of 0 or 1; life expectancy more than 6 months; adequate bone marrow function (e.g., total white blood cells ≥2000/mm³, hemoglobin ≥9 g/dL, granulocyte count >1000/mm³, and platelet count ≥100,000/mm³); adequate liver function (total serum bilirubin <1.5 mg/dL, aspartate aminotransferase, and alanine aminotransferase ≤5 times upper limit of normal); adequate renal function (serum creatinine <2.0 mg/dL and/or creatinine clearance ≥60 mL/min); major surgery, chemotherapy, radiotherapy, or immunotherapy terminated at least 6 weeks and recovery from the toxic effects of these treatments; positive for histochemical staining of both survivin and MUC1 in tumor regions. Patients were excluded if they had a clinically significant cardiac abnormalities, severe cardiovascular, decompensated heart insufficiency, ventricular rhythm disorders, coagulation disorders, active inflammatory disease, positive for hepatitis B/C or HIV, history of an autoimmune disease (e.g., systemic lupus, rheumatoid arthritis, and others), severe psychiatric disease, known immunosuppressive disease or use of immunosuppressive drugs (steroids), or history of other neoplasms, and pregnancy or lactation. Histologic type and Tumor Node Metastasis (TNM) classification were classified, according to the criteria of the American Joint Commission on Cancer (AJCC) [48].

Written informed consent was obtained from all the patients. This study was approved by the ethics committee of the Third Affiliated Hospital of Kunming Medical University and was carried out in accordance with criteria of Good Clinical Practice (GCP). The ethical approval reference number is KY2009-iAPA.

Generation of modified-DC vaccine
DCs were generated from peripheral blood mononuclear cells (PBMCs) from each patient using the Cobe Spectra Apheresis System (GambroBCT, USA). PBMCs were cultured for six days in serum-free, GMP (Good Manufacturing Practice) certified medium supplemented with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) to obtain immature dendritic cells (iDC). The PBMCs were isolated by leukapheresis, and then re-suspended in serum-free media at 37 °C in a humidified 5% CO₂/95% air incubator. After incubation for half an hour, non-adherent cells were removed, and the adherent cells were cultured in media supplemented with 30 ng/mL recombinant human interleukin 4 (IL-4, Proteck, R&D systems, USA), 100 ng/mL recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF; R&D systems, USA), and 2% human serum albumin and 2 mmol/L glutamine for 6 days. Fresh media supplemented with the cytokine were added every other day. Then iAPA cytokine (10,000 vp/cell) that includes SOCS1-specific small interfering RNA and peptides for Flagellin, survivin, and MUC1 were added to the culture at day 6. The matured DCs were harvested by vigorous washing with sterile 0.9% NaCl solution. The matured DCs were confirmed using flow cytometry analysis before vaccination were harvested, washed, and re-suspended in 100 mL of sterile 0.9% NaCl solution containing 1% serum albumin (Baxter, Austria).

Vaccination of the modified-DC vaccine
The protocol was an open-label, uncontrolled, and dose-escalation phase I trial. This phase I trial was not retrospectively registered in ClinicalTrials.gov. Patients were intravenously injected with 1 × 10⁶, 1 × 10⁷ and the maximum dose DC vaccine suspended in 100 mL of sterile 0.9% NaCl solution containing 1% serum albumin at day 7, 14 and 21, respectively (Fig. 1). Dose escalation proceeded using a 3 + 3 cohort design [49]. First, according to eligibility criteria, 3 patients were enrolled and divided into low dose groups, who were intravenously injected with 1 × 10⁶ DC vaccine. Adverse events (AEs) were observed at 0, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 48, and 72 h after each injection using Common Terminology Criteria for
Adverse Events version 4 (CTCAE 4). If there were no unanticipated or serious adverse events occurred in the 28-day period, 3 another patients were enrolled into the middle dose group for $1 \times 10^7$ DC vaccine. AEs were also observed, and if there were no unanticipated or serious adverse events, then enrolled 9 patients into the high dose group for the maximum dose DC vaccine. If there were unanticipated or serious adverse events occurred in any stage, the clinical trial would be ended.

**Immunohistochemical staining**

Paraffin-embedded NSCLC lung samples were cut to 4 µm. All sections were baked at 70 °C for 1 h, hydrated with xylene and alcohol as routine, and microwaved in a citrate buffer (pH 6.0) for 5 min for antigen retrieval. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 30 min. Then the sections were incubated with mouse monoclonal anti-survivin (1:10 R&D Systems, Minneapolis, MN, USA) and anti-MUC1 (1:200, Abcam, Cambridge, UK) in phosphate-buffered saline (PBS; pH 7.4) overnight, followed by washing three times with PBS. The slides were incubated with an ABC kit (Vector, Burlingame, CA, USA), according to the manufacturer’s instructions, color developed with 3-3’-diaminobenzidine (DAB; Dako Corporation, Carpinteria, CA, USA), and counter stained with hematoxylin. Gastric carcinoma section was used as a negative control, and the pre-immune serum was used as a positive control.

**Evaluation of survivin and MUC1 expression**

Survivin staining was evaluated, according to semiquantitative method [20]. The staining intensity was graded as follows: 1+ (weak), 2+ (moderate), and 3+ (intense). The grade of positive staining (mean percentage) was assigned as follows: 0 (< 5%), 1 (5–25%), 2 (26–50%), 3 (51–75%), and 4 (>75%). The two grades were then multiplied to derive a score for each sample. MUC1 staining was evaluated, according to semiquantitative analysis [50] as follows: (negative), 1+ (weak), 2+ (moderate), and 3+ (intense). The positive staining (mean percentage) for MUC1 was assigned as follows: 1 (<10%), 2 (10–50%), and 3 (51–100%). Scoring was independently performed by two pathologists blinded to clinical outcome and reached a consensus for all slides.

**Analysis of DC phenotype by flow cytometry**

The purity and phenotype of modified-DC was analysed using FACS Canto II flow cytometer (BD Biosciences, USA). Cells were stained with fluorescein isothiocyanate (FITC)-conjugated CD86, phycoerythrin (PE)-conjugated CD80, CD14, and HLA-DR, allophycocyanin (APC)-conjugated CD83, CD40, CD54, and HLA-ABC monoclonal antibodies (BD Biosciences, USA), and PE-conjugated CCR7 monoclonal antibody (R&D systems, USA). FITC-, APC-, PE-mouse isotype immunoglobulins, and PE mouse anti-human HLA-DR were used as background controls.

**Lymphocyte populations**

T cell subsets, including CD3+CD4+, CD3+CD8+, CD3+Va24+, CD3+CD56+, and CD3+CD4+CD25+FoxP3+, and NK cell CD16+CD56+ in PBMCs were analysed using FACS Canto II flow cytometer prior vaccination to vaccination on day 14 (7 days post the first vaccination), day 21 (7 days post the second vaccination), and day 28 (7 days post the third vaccination). Cells were stained with FITC-labeled CD3, CD4, and CD56, APC-labeled CD3, CD4, and CD25, PE-labeled CD8, CD16+CD56, FoxP3, and TCR-Va24, and PerCP-labeled CD45 antibodies (BD Biosciences, USA). The data were analysed by Cell Quest software (FACS Diva, BD Biosciences, USA). FITC-, APC-, PE-, and PerCP- mouse isotype immunoglobulins were used as background controls for nonspecific immunofluorescence.

**Patient assessment**

Adverse events (AEs) were observed at 0, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 48, and 72 h after each injection using Common Terminology Criteria for Adverse Events version 4 (CTCAE 4). Clinical responses were evaluated using computed tomography (CT) at one week after the last modified DC vaccine was injected. Immunologic responses and tumor markers were assayed before injection of the modified-DC vaccine at day 7, 14, 21, and 28. Health-related quality of life was evaluated by the EORTC QLQ-C30 Scoring Manual before vaccination and at one week after the last injection. Function of vital organs was monitored by laboratory data and electrocardiography (ECG).

**Cytokine secretion assay**

The changes of interleukin-2 (IL-2), IL-4, IL-6, and IL-10, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) in the sera of the patients were assessed at day 0, 14, 21, and 28. Sera from the patients were stored at −20 °C before measuring cytokine levels using a human Th1/Th2 cytokine kit II (BD Biosciences, USA) by Cytometric Bead Array (CBA).

**Statistical analysis**

Statistical analyses were performed using SPSS16.0 (SPSS Inc., Chicago, IL, USA). Modified-DC phenotypes were expressed as mean ± SD and analysed by the paired-samples $t$-test for normal distribution. Wilcoxon matched-pairs signed-ranks test was used for non-normal distribution. Tumor markers, cytokines, and T
cell populations were determined by repeated measurement analysis of variance (ANOVA). Wilcoxon rank sum test was used to analyze Quality-of-Life. A p-value <0.05 was considered statistically significant.

Results
Patient characteristics
15 patients with resected stage I to IIIA NSCLC were enrolled in this dose-escalation study from August 2012 to September 2013. Three patients were treated with $1 \times 10^6$ of modified-DC vaccines; another three patients were treated with $1 \times 10^7$; and nine patients were treated with maximum dose $8 \times 10^7$ of modified-DC vaccines. Patient characteristics are shown in Table 1. Median age was 50 years (range from 40 to 61 years), and 15 patients had Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0. The histologic subtypes of patients include adenocarcinoma, squamous carcinoma, and adenosquamous carcinoma. Immunohistochemical analysis of survivin and MUC1 expression in the tumor biopsies prior to vaccination were both positive in all patients. Survivin expression was observed mainly in the cytoplasm and a little in the nucleus and cytoplasmic membrane, with staining scores of 1+, 2+ and 3+ in 4 (26.7%), 9 (60%), and 2 (13.3%) specimens, respectively. MUC1 expression was observed mainly in the membrane, with staining scores of 2+ and 3+ in 9 (60%), and 6 (40%) specimens, respectively (Fig. 2).

Safety and toxicity
Before injected into patients, we detect the safety and the viability of the DC vaccines. All Trypan blue viability was ≥70%, and for there is no growth for bacterial and fungal, endotoxin assay is <5 EU/mL, and Mycoplasma (PCR) is negative. Dose-limiting toxicity was not observed by vaccination with the modified-DC vaccines. The most common adverse events (AEs) were grade 1 flu-like symptoms which did not require any intervention, including pyrexia (40%), fatigue (33.33%), C-reactive protein (CRP) increased (46.67%), myalgia (40%), abdominal pain (33.33%), and nausea (20%). Pyrexia and myalgia commonly occurred in the group immunized with the maximum amount of the vaccine in 5 of 9, and 4 of 9 patients, respectively. One of the patients in the maximum amount vaccine immunized group developed the Grade 1 pyrexia and had the highest temperature 38.9 °C within 4 to 10 h, but the temperature decreased to normal levels within 10 to 20 h after the vaccine infusion. No unanticipated or serious adverse events occurred in the 28-day period. The numbers of vaccination-related AEs are summarized in Table 2a-b.

Modified-DC phenotypes
Final modified-DC sup-regulated immunostimulatory molecule expression on the cell surface. The number of cell populations with CD14 expression was down-regulated from 88.3 ± 7.08% to 19.88 ± 20.28%; the cell population with HLA-ABC expression was down-regulated from 97.01 ± 5.05% to 92.5 ± 8.14%; the cell population with co-stimulatory molecule CD80, CD86, and CD40 was dramatically up-regulated, from 0.99 ± 0.58% to 70.46 ± 25.37%, 5.71 ± 3.46% to 58.24 ± 17.66%, and 1.57 ± 1.90% to 37.02 ± 31.59%, respectively; the cell population with the expression of maturation marker, CD83 and CD54, was also up-regulated from 1.91 ± 1.81 to 28.83% ± 17.57 and 90.6 ± 9.09% to 99.51 ± 0.64%, respectively. Meanwhile, the expression of C-chemokine receptor 7 (CCR7) which induces DC maturation and activation signals remained almost unchanged from

| Characteristics                  | No. of Patients | %    |
|----------------------------------|----------------|------|
| Sex                              |                |      |
| Female                           | 3              | 20   |
| Male                             | 12             | 80   |
| Age, years                       |                |      |
| Median                           | 50             |      |
| Range                            | 40–61          |      |
| ECOG PS                          |                |      |
| 0                                | 15             | 100  |
| Histologic subtypes              |                |      |
| Adenocarcinoma                   | 10             | 66.7 |
| Squamous carcinoma               | 4              | 26.7 |
| Adenosquamous carcinoma          | 1              | 6.7  |
| Tumor stage (AJCC)               |                |      |
| IA                               | 4              | 26.7 |
| IB                               | 6              | 40   |
| IIA                              | 2              | 13.3 |
| IIB                              | 1              | 6.7  |
| IIIA                             | 2              | 13.3 |
| Lymph node metastasis            |                |      |
| Yes                              | 2              | 13.3 |
| No                               | 13             | 86.67|
| History of chemotherapy          |                |      |
| Yes                              | 12             | 80   |
| No                               | 3              | 20   |
| History of radiotherapy          |                |      |
| Yes                              | 0              | 0    |
| No                               | 15             | 100  |

Abbreviations: ECOG Eastern Cooperative Oncology Group, PS Performance status
25.15% ± 32.81 to 19.55% ± 25.78 ($p > 0.05$). The cell populations associated with modified-DC are shown in Fig. 3.

**Patient immune responses**

The lymphocyte subgroups and the production of cytokines of all 15 patients were analyzed for prior to and post the vaccination at day 14, 21, and 28. The T cell subgroups included CD3⁺CD4⁺, CD3⁺CD8⁺, CD3⁺CD56⁺, CD3⁺Va24⁺, and CD3⁺CD4⁺CD25⁺Foxp3⁺, as well as CD3⁺CD16⁺CD56⁺ NK cells. The percentages of CD3⁺CD8⁺ T cells, CD3⁺CD56⁺ natural killer T (NKT) cells, CD3⁺Va24⁺ iNKT cells, and CD3⁺CD16⁺CD56⁺ NK cells did not increased significantly ($p > 0.05$). No apparent change in the percentage of CD3⁺CD4⁺ ($p > 0.05$) was observed. However, the percentage of CD3⁺CD4⁺CD25⁺Foxp3⁺ T regulatory (Treg) cells was significantly decreased starting from day 14 ($p < 0.05$, Fig. 4).

The cytokines IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α were observed in all the patients. The levels of IL-2, IL-4, IL-10, and IFN-γ were not significantly increased compared to pre-vaccination ($p > 0.05$, Fig. 5a). However, the TNF-α levels were significantly increased in 2 of 15 patients from 1.81 to 10.86 pg/mL and from 2.43 to 13.07 pg/mL, respectively (Fig. 5b). The IL-6 levels were also significantly increased in two patients from 4.03 to 67.23 and from 4.14 to 87.96, respectively (Fig. 5c).

**Clinical response**

In this phase I clinical trail, 15 patients with resected stage I to IIIA NSCLC were enrolled, all patients had no visible tumor lesions pre- and 1 month after vaccination injection. Meanwhile, the tumor markers CEA, SCC, CYFRA21, and CA125 were analysed in all the patients.13 patients had normal tumor markers at baseline, and only 2 patients had abnormal tumor markers. The carcino-embryonic antigen (CEA) levels were decreased in patient No.14 patient (Fig. 6a), and the CYFRA21 levels were decreased to normal levels in No.15 patient after the vaccination (Fig. 6b). The other tumor markers remained almost at normal levels. Meanwhile, the patients’ quality of life improved after the vaccination as the score of the quality of life was significantly decreased, compared to pre-vaccination ($p < 0.05$). Furthermore, patients’ quality of life was significantly improved in the high-dose group, compared with low-dose and middle-dose groups after the treatment ($p < 0.05$, Fig. 7).

More importantly, in the long-term follow-up until 2017, 1 patient had no recurrence, 1 patients had a progressive disease (PD), and 1 patient was died on May 1, 2015 in the low dose group. In the middle dose group, all 3 patients had no recurrence. In the high dose group, 1 patient was died on 21 April, 2015, 1 patient had a PD, and the other 7 patients had no recurrence.

**Discussion**

NSCLC accounts for 85% of lung cancer. Surgery following platinum-based chemotherapy and radiation is still the primary treatment for resectable stage I to IIIA NSCLC. However, the prognosis is poor, and 5-year survival rate of all stages is only 16%. Therefore, vaccination is the first and essential choice for NSCLC prevention. In this study, we developed a novel modified-DC vaccine that was pulsed with survivin and MUC1, silenced with SCOS1, and immune-stimulated with flagellin. We performed a phase I
clinical trial of the vaccine in patients with resected NSCLC. The vaccine had a modest antitumor activity without dose-limiting toxicity. Notably, the positive cytokines were increased, and the negative lymphocytes were decreased as compared to baseline. Thus, vaccination with the modified-DC vaccine modulated the tumor microenvironment to elicit an immune response against the tumor. We found the CEA levels were decreased in No.14 patient, and the CYFRA21 returned to normal levels in No.15 patient. The quality of life of patients immunized with the maximum dose of vaccine was significantly improved after the vaccination. The novel DC vaccine enhanced DC differentiation and antigen presentation feature, and

Table 2 National Cancer Institute Common Toxicity Criteria for Adverse Events in study population (n = 15)

| A | Adverse Event | Total, n (%) | Grade 1–2 | Grade 3–4 |
|---|---|---|---|---|
| N=15 | Any Grade | Grade 1–2 | Grade 3–4 | Grade 3–4 |
| Pyrexia | 6 (40%) | 6 (40%) | 0 |
| Fatigue | 5 (33.33%) | 5 (33.33%) | 0 |
| Palpitate | 1 (6.67%) | 1 (6.67%) | 0 |
| Headache | 3 (20%) | 3 (20%) | 0 |
| Chest pain | 1 (6.67%) | 1 (6.67%) | 0 |
| Chest Congestion | 1 (6.67%) | 1 (6.67%) | 0 |
| Abdominal pain | 5 (33.33%) | 5 (33.33%) | 0 |
| Abdominal distension | 2 (13.33%) | 2 (13.33%) | 0 |
| Nausea | 3 (20%) | 3 (20%) | 0 |
| Hypertension | 1 (6.67%) | 1 (6.67%) | 0 |
| Nasal congestion | 1 (6.67%) | 1 (6.67%) | 0 |
| CRP increased | 7 (46.67%) | 7 (46.67%) | 0 |
| Myalgia | 6 (40%) | 6 (40%) | 0 |
| Creatinine increased | 2 (13.33%) | 2 (13.33%) | 0 |
| Chills | 1 (6.67%) | 1 (6.67%) | 0 |

| B | Adverse Event | 1 × 10⁶, n (%) | 1 × 10⁷, n (%) | Maximum numbers of cultured cell, n (%) |
|---|---|---|---|---|
| Any Grade | Grade 1–2 | Grade 3–4 | Any Grade | Grade 1–2 | Grade 3–4 | Any Grade | Grade 1–2 | Grade 3–4 |
| Pyrexia | 0 | 0 | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 5 (55.56%) | 5 (55.56%) | 0 |
| Fatigue | 1 (33.33%) | 1 (33.33%) | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 3 (33.33%) | 3 (33.33%) | 0 |
| Palpitate | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Headache | 1 (33.33%) | 1 (33.33%) | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 1 (11.11%) | 1 (11.11%) | 0 |
| Chest pain | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Chest Congestion | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Abdominal pain | 3 (100%) | 3 (100%) | 0 | 0 | 0 | 0 | 2 (22.22%) | 2 (22.22%) | 0 |
| Abdominal distension | 0 | 0 | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 1 (11.11%) | 1 (11.11%) | 0 |
| Nausea | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 2 (22.22%) | 2 (22.22%) | 0 |
| Hypertension | 0 | 0 | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 |
| Nasal congestion | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 0 | 0 |
| CRP increased | 2 (66.67%) | 2 (66.67%) | 0 | 1 (33.33%) | 1 (33.33%) | 0 | 4 (44.44%) | 4 (44.44%) | 0 |
| Myalgia | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 4 (44.44%) | 4 (44.44%) | 0 |
| Creatinine increased | 0 | 0 | 0 | 2 (66.67%) | 2 (66.67%) | 0 | 0 | 0 |
| Chills | 1 (33.33%) | 1 (33.33%) | 0 | 0 | 0 | 0 | 0 | 0 |
strongly activated antigen-specific T cell immune response by survivin and MUC1 pulsing and SOCS1 silencing and stimulation of TLR signaling.

The vaccination-related AEs were reported to be under lower grade category within the 28-day period. Therefore, this novel modified-DC vaccine did not exhibit unanticipated or serious AEs. Of note, the incidence of CRP increased, and the occurrence of pyrexia and myalgia in the highest dose group were high. The patient numbers 10 and 14 experienced myalgia and pyrexia accompanied by increased CRP and had the highest temperature 38.9 °C and 38.8 °C, respectively. In fact, CRP, the major acute-phase reactant in humans, increases rapidly in response to inflammatory stimuli to recognize pathogens and damage cells [51]. Thus, better anti-tumor effects might be seen in patients who experienced major adverse events.

The two patients 10 and 14 who experienced myalgia and pyrexia accompanied by increased CRP also showed elevated IL-6 levels, with the highest levels 67.23 pg/mL and 87.96 pg/mL, respectively. This is in line with the findings in another study in which IL-6, as an important mediator of fever, is responsible for stimulating acute phase protein CRP synthesis [52]. On the one hand, IL-6 changes the temperature set point to increase body temperature [53] and stimulates energy mobilization in muscle and fatty tissues to increase body temperature. IL-6 is also a myokine that is produced from muscle and elevated in response to muscle contraction [54]. Meanwhile, IL-6 is secreted by T cells and macrophages in response to TLRs, leading to inflammatory cytokine production [55]. In addition, IL-6 also stimulates T lymphocyte proliferation, influences growth, differentiation, and migration of tumor cells, and stimulates angiogenesis [56]. Therefore, the elevated IL-6 levels secreted by T cells in patients 10 and 14 might indicate successful targeting of tumor cells. In fact, the increases in the inflammatory cytokines, and IFN-γ and IL-6 coincide with the onset of the tumor lysis syndrome after modified T cell infusion [57].

Fig. 3 The phenotypes of Modified-DC (HLA-ABC/HLA-DR/CD80/CD86/CD40/CD83/CD54/CCR7) by flow cytometry analysis. a The pooled data (n = 15) represents modified-DC phenotypes of pre- and post-culture. Results represent mean ± standard deviation. The cell population with HLA-DR/CD80/CD86/CD40/CD83/CD54 phenotype in matured modified-DCs were significantly increased compared with pre-culture (n = 15; *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, no significant); the cell population with HLA-ABC and CCR7 phenotype in matured modified-DCs were decreased compared with pre-culture (n = 15, p < 0.05 and p > 0.05, respectively). b Representative data of different cell populations in matured and pre-cultured DCs.

Ge et al. BMC Cancer (2017) 17:884
In this study, patients 10 and 3 after the vaccination had significant increases in IL-6 and TNF-α, respectively. Patient 14 featured increases in both IL-6 and TNF-α. The levels of IL-6 were 21 times higher than baseline levels, and the highest level of IL-6 showed up at 21 to 28 days after the first modified-DC vaccine infusion. The temporal rise in cytokine levels paralleled the clinical symptoms as mentioned above.

The serum levels of IL-6 were increased after the vaccination, indicating the activation of T cells and induction of immune response by the host. This is consistent with the previous findings that SOCS1-silenced DCs could produce cytokines, including IFN-γ, IL-12, TNF-α, and IL-6 [36]. The cytokines secreted by immune cells play an important role in immunotherapy. Cytokine changes are used to represent the

![Fig. 4](image_url) Lymphocyte subgroups with pre-vaccination (day 0) and post-vaccination (day 14, 21, and 28) as by flow cytometry. a The bar graph represent mean ± standard deviation (n = 15). The percentages of CD3+CD4+ T cells, CD3+CD8+ T cell, CD3+CD56+ natural killer T (NKT) cell, CD3+Vα24+ NKT cell, and CD3+CD16+CD56+ NK cell populations were not significantly increased (p > 0.05). The percentage of CD3+CD4+CD25+Foxp3+ T regulatory cells (Tregs) population was significantly decreased starting from day 14 (*, p < 0.05). b Representative dot plot (gated on CD3+CD4+CD25+Foxp3+ Tregs of post-and pre-vaccination)

![Fig. 5](image_url) Levels of cytokines IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α. Percentage changes in individual cytokine levels are represented in line graphs (a). Comparisons of the levels of individual patients for TNF-α (b) and IL-6 (c) levels are indicated with respect to time
strength of immune response [58]. Type-1 T helper (Th1) cells mainly produce IL-2, IFN-γ, and TNF-α that drive cytotoxic T cell (CTL) response and induce high levels of anti-inflammatory response [59]. In contrast, type-2 T helper (Th2) cells produce IL-4, IL-6, and IL-10 that are responsible for humoral immunity to stimulate B cell proliferation and produce immunoglobulin [59]. The imbalance of Th1 and Th2 is related to tumor immune escape and the pathogenesis of various diseases [60]. TNF-α, another Th1 cytokine produced by activated T cells, is able to induce tumor cell necrosis and enhance the activity of NK and T cells [61].

Furthermore, the analysis of lymphocyte subsets is also a useful way to evaluate immune response [62]. The modified-DC vaccine was found to inhibit production of the Treg cell proliferation, which is an immune suppressing lymphocyte. There were no obvious
changes in CD3+CD4+CD8+, CD3+CD4+CD8+, CD3−Va24+, CD3+CD56+, orCD3+CD16+CD56− cell population between the patients before and after vaccination, but CD3+CD4+CD25+Foxp3+ Treg cell number was significantly decreased after a transient increase at day 14 (p < 0.05). Treg cells play critical role in maintaining immune tolerance through suppressing the effector T cell responses as well as the activity of DC [63]. Increased number of Treg cells in multiple tumors is correlated with a poorer prognosis [64−66]. TLR5 agonists inhibit the function or number of Treg cells to suppress tumor growth [67].

While efficacy was not the primary end point of this trial, we found evidence of mild anti-tumor activity. In this phase I clinical trial, all the patients enrolled were not found visible tumor lesions in the baseline, and 1 month after treatment all patients did not get tumor recurrence. Meanwhile, we analysed the tumor markers such as CEA, SCC, CYFRA21, and CA125. 1 patient experienced a decrease in tumor marker CEA and the other had normal levels of tumor marker CYFRA21. It is interesting that patient 14 experienced a significant increase in CRP, IL-6, and TNF-α level, but a significant decrease in tumor marker CEA levels. It is possible that there was a combination of cytokine and lymphocyte induced clinical response. This may be the limitation of the DC vaccine. The small number of patients in this study is another potential limitation of this study.

Moreover, this modified DC vaccine maybe a potential treatment for patients with resected NSCLC to prevent recurrence. In all the patients, only 2 patients died about 2 years after injecting the vaccine, and 2 patients had a PD, 11 patients were still with recurrence-free survival (RFS). Also, there is another limitation of the current study which is that there is no potential way of knowing the effect of the vaccine on reducing tumor volume. In this clinical trial where no objective response rate (ORR) of the tumour occurred, the benefits could have been falsely attributed to the DC vaccine therapy.

Conclusion
In conclusion, a novel survivin and MUC1 pulsed DC vaccine with silenced SOCS1 and stimulated TLR immune was developed in this study and exhibited convincing phase I trial outcomes in preventing NSCLC. Further more, the vaccine maybe a very efficacious treatment for patients with resected NSCLC to prevent recurrence. Our findings provide a potential DC vaccine for NSCLC, which is worthy of a future phase II/III clinical trial.

Abbreviations
AEs: Adverse events; AJCC: American Joint Commission on Cancer; ANOVA: Analysis of variance; APC: Allophycocyanin; CEA: Carcino-embryonic antigen; CTCAE 4: Common Terminology Criteria for Adverse Events version 4; CTL: Cytotoxic T-lymphocyte; DC: Dendritic cell; ECOG PS: Eastern Cooperative Oncology Group Performance Status; FITC: Fluorescein isothiocyanate; IAP: Inhibitor of apoptosis protein; IFN-γ: Interferon gamma; IL-4: Interleukin 4; NAT: Natural killer T; NSCLC: Non-small cell lung cancer; PAP: Prostatic acid phosphatase; PBMCs: Peripheral blood mononuclear cells; PE: Phycoerythrin; SOCS1: Suppressor of cytokine signaling 1; TLR: Toll-like receptor; TNF-α: Necrosis factor alpha; TNM: Tumor Node Metastasis; Treg: T regulatory

Acknowledgements
Not applicable.

Funding
This study was supported in part by grants from National Science and Technology Support Program (#2015BA112B12), National Key Technology Research and Development Program of The 12th Five-Year Plan of China (#2011ZX09102-001-20), National Natural Science Foundation of China (#81502222, #81260307, #81470006, #81600185 and #81602029), National Clinical Key Specialty Construction Projects of Oncology of National Health and Family Planning Commission of China (Awarding to Tumor Hospital of Yunnan Province: 2013−2014), the Yunnan Province Leading Talent Program of Health System(L-201213). The the funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All supporting data for the conclusions are included within the article.

Authors’ contributions
Conception and design: Xin Song, Siyi Chen and Haifeng Song; acquisition of data: Chunlei Ge, Tao Geng, Ruilei Li, Suwei Dong, Zhivei Zhang, and Na Zhang; analysis and interpretation of data: Jinyan Yang, Qinghua Tan, Linfeng Song, Ying Wang, Yuanbo Xue, Jiyin Guo, and Lin Hua; manuscript writing: Chunlei Ge, Tao Geng, and Xin Song. Revision manuscript: Chunlei Ge, Ruilei Li and Zhen Li. All authors contributed to the intellectual content of the article and read and approved the submitted manuscript.

Ethics approval and consent to participate
This study was approved by the ethics committee of the Third Affiliated Hospital of Kunming Medical University and was carried out in accordance with criteria of Good Clinical Practice.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan 650118, China. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. 3 Department of Immunology, Baylor College of Medicine, Houston, TX, USA. 4 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

Received: 15 July 2016 Accepted: 29 November 2017

Published online: 21 December 2017

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69−90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(4):9−29.
3. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, Thun M. Global Cancer Facts & Figures 2007. Atlanta. 2007;7:2007(1):52.
4. Rami-Porta R, Crowley JJ, Goldstraw P. Review the revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;155.
5. Scaglioni GV, Parikh P, Von Pawel J, Bisma B, Vansteenkiste J, Manegold C, Servatovski P, Gatzemeier U, Digumarthy R, Zukin M, Phase III. Study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin Oncol. 2008;26:3543–51.

6. Schiller JH, Harrington D, Belani CP, Langer S, Sandler A, Krook J, Zhu J. Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.

7. Mok TS, Y-L W, Thongprasert S, Yang CH, Chu D-T, Saigo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hish V, Thongprasert S, Campos D, Maaleekoonprij S, Smylie M, Martini R. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:133–22.

9. Shaw AT, Yeap BY, Solomon BJ, Engelman JA, Shapiro GI, Brahmer J, Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Chu D-T. Phase II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. J Cancer Ther. 2008;6:955–64.

10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Chu D-T. Phase II study of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27:4481–6.
